ArticleTranslational cancer research2025
Silencing PPA1 promotes the survival of non-small cell lung cancer A549 cells under glucose-starved conditions.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-small cell lung cancer (NSCLC) is a malignant tumor with extremely high morbidity and mortality. The large demand for energy during its progression is highly dependent on glucose. The energy metabolism enzyme inorganic pyrophosphatase 1 (PPA1) can mediate the progression of NSCLC through various pathways. Bioinformatics analysis revealed a potential relationship between PPA1 and glycolysis pathway. This study further examined the regulatory effect of silencing PPA1 on the survival of A549 human NSCLC cells under glucose-starved conditions. Methods: The glycolysis-related gene set was obtained through the gene set enrichment analysis (GSEA) of the Molecular Signatures Database to form a glycolysis gene set, and the potential relationship between PPA1 and glycolysis pathway-related proteins was preliminarily examined via the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database. After A549 cells were treated with glucose-free RPMI-1640 medium for 0, 12, and 24 h, the expression level of PPA1 protein was detected via Western blotting (WB). Further stable silencing of PPA1 and cell proliferation activity were analyzed by Cell Counting Kit-8 (CCK-8), colony formation, and cell cycle assays, and cell apoptosis was analyzed via propidium iodide/annexin V cell flow cytometry. The expression of cell proliferation-related proteins p21, CDK2, Ki-67, and p53 and that of cell apoptosis-related proteins BAX, cleaved caspase-3, and cleaved PARP were detected via WB. Results: Bioinformatics was employed to examine the potential relationship between PPA1 and glycolysis pathway-related genes, and the results showed that there was a certain connection between PPA1 and the glycolysis pathway. With the extension of the treatment time of A549 cells with glucose-free medium, the expression of PPA1 showed a progressive increase. After further silencing of PPA1, the functional experiment results under glucose-free culture conditions showed that compared with those in the empty vector control (shCtrl) group, the cell viability, cell clone formation number, and S-phase cell percentage in the shPPA1-1 group and shPPA1-2 group were significantly increased under glucose-starved conditions, while the number of apoptotic cells was significantly reduced (P<0.05). Additionally, the WB results showed that compared with the shCtrl group, the shPPA1-1 group and shPPA1-2 group exhibited upregulated expression of Ki-67 and CDK2 proteins but downregulated expression of the p21, p53, cleaved PARP, cleaved caspase3, and BAX proteins (P<0.05). Conclusions: Under glucose-starved conditions, silencing PPA1 can promote the survival of A549 cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.